Usage Examples
- The sponsor filed an MAA via the centralised procedure after completion of the US NDA.
- CHMP issued a positive opinion on the MAA after two clock-stop cycles.
- Accelerated assessment cut the MAA review from 210 days to 150.
What is Marketing Authorization Application (MAA)?
Marketing Authorization Application (MAA) is the dossier a sponsor files to place a medicine on the European Union market. Unlike a US NDA, it is granted by the European Commission on EMA's scientific recommendation.
A Marketing Authorization Application exists because a company cannot place a medicine on the European market on its own assessment. The MAA is the instrument that moves the entire evidence base, quality, non-clinical and clinical, to an authority empowered to refuse it. Until that authority decides, the product has no legal status as a medicine in the EU.
An MAA covers the finished medicinal product a sponsor intends to sell: its quality, safety, efficacy, product information and risk management, assembled into a single dossier. An MAA does not cover permission to run the trials that produced the data, which is a separate clinical trial authorisation, and it does not settle pricing or reimbursement, which stay national decisions.
An MAA is run against a clock in practice. Under the centralised procedure the assessment takes up to 210 active days, and because those are active days rather than calendar days, elapsed time is longer. CHMP issues the scientific opinion, then the European Commission takes the legally binding decision that is valid across the EU and the EEA.
Not to be confused with
- NDA
- an NDA is filed to FDA, which both reviews and approves it. An MAA is assessed by EMA but granted by the European Commission, so a positive CHMP opinion is a recommendation, not an authorization.
- Clinical trial application
- a CTA authorises the study that generates the data; an MAA authorises the sale of the product built on that data. Filing an MAA does not reopen or depend on any CTA decision.
- Marketing authorisation
- the MAA is the application; the marketing authorisation is the decision issued at the end of it. Only the granted authorisation permits sale, and the two are routinely conflated in project plans.
- eCTD
- eCTD is the electronic format the dossier is transmitted and lifecycled in, not the application itself. Changing format changes nothing about the content obligations of the MAA.
The obligations below are the ones that shape MAA planning under the centralised procedure.
What you must do
- 1Submit a single application to EMA rather than separate national dossiers when using the centralised procedureCentralised procedure, single EU-wide application
- 2Plan the programme around up to 210 active assessment days, and treat that number as active time rather than calendar timeCHMP evaluation, 210 active days
- 3Hold all EU commercialisation until the European Commission takes its legally binding decision, not at the CHMP opinionEuropean Commission decision
- 4Justify major public health interest, with emphasis on therapeutic innovation, to obtain accelerated assessment at 150 daysAccelerated assessment, 150 days
- 5Scope launch, supply and pharmacovigilance planning to all EU Member States plus Iceland, Liechtenstein and Norway once the authorisation is grantedEU and EEA validity
Common mistakes
Reading 210 days as elapsed time
the figure counts active assessment days only. Periods when the file sits with the sponsor are not active days, so launch plans, supply forecasts and investor timelines built on 210 calendar days miss by months.
Treating a positive CHMP opinion as approval
CHMP issues an opinion; the European Commission is the authorising body and takes the legally binding decision. Announcing availability or shipping product on the opinion alone puts a company ahead of its own legal basis to sell.
Confusing authorisation with market access
the Commission's decision permits sale across the EU and EEA, but pricing and reimbursement remain national decisions. Revenue models keyed to the authorisation date, rather than to country-by-country access, overstate the first two years.
When This Matters
- The sponsor filed an MAA via the centralised procedure after completion of the US NDA.
- CHMP issued a positive opinion on the MAA after two clock-stop cycles.
- Accelerated assessment cut the MAA review from 210 days to 150.
Frequently Asked Questions
An MAA seeks authorization to market a medicine in the European Union, while an NDA seeks US approval from FDA. The jurisdictions differ, and so does the decision-maker: the European Commission issues the binding EU decision on EMA's recommendation, whereas FDA both reviews and approves an NDA.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
